Ionis Pharmaceuticals' liabilities need constant monitoring ...
Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment